Nasdaq
Every company in the roster listed on Nasdaq.
Every company in the roster listed on Nasdaq.
292 of 292 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Longeveron (NASDAQ: LGVN)LGVN · Nasdaq | 1 asset: 1 Ph 2 | LaromestrocelPhase 2 · Alzheimer's DiseaseWeak signal | None on record | $60M | $7.3MSep 2026 | ~1.6 qtrs | $12M |
Cognition TherapeuticsCGTX · Nasdaq | 1 asset: 1 Ph 2 | ZervimesinePhase 2 · Alzheimer's DiseaseWeak signal | 31 May 2027Zervimesine · Phase 2 | $57M | $31MSep 2026 | ~8.2 qtrs | $27M |
Corbus PharmaceuticalsCRBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | Sutantatug envedotinPhase 3 · Cervical Cancer | 16 Jan 2027Sutantatug envedotin · Phase 1/2 | $57M | $115MSep 2026 | ~5.0 qtrs | $104M |
Oncolytics Biotech Inc.ONCY · Nasdaq | 1 asset: 1 Ph 2 | PelareorepPhase 2 · Advanced Metastatic Colorectal Cancer | 30 Jul 2027Pelareorep · Phase 1/2 | $56M | $2.4MSep 2026 | Ended Oct 2026 | ~$19M |
Tonix PharmaceuticalsTNXP · Nasdaq | 5 assets: 3 approved, 2 Ph 2 | TNX-1300Phase 2 · Cocaine Intoxication | Feb 2028cyclobenzaprine · Phase 2 | $55M | $163MSep 2026 | ~3.9 qtrs | $80M |
Veru Inc.VERU · Nasdaq | 1 asset: 1 Ph 2 | enobosarmPhase 2 · ObesityPartial signal | Oct 2027enobosarm · Phase 2 | $53M | $24MJun 2026 | ~3.1 qtrs | $16M |
Gain Therapeutics, Inc.GANX · Nasdaq | 1 asset: 1 Ph 2 | GT-02287Phase 2 · Parkinson's Disease | 30 Jun 2028GT-02287 · Phase 2 | $49M | $12MSep 2026 | ~2.7 qtrs | $8.7M |
Clene NanomedicineCLNN · Nasdaq | 1 asset: 1 Ph 3 | CNM-Au8Phase 2/3 · Multiple SclerosisPartial signal | None on record | $48M | $10.0MSep 2026 | ~2.4 qtrs | $14M |
Apollomics Inc.APLM · Nasdaq | 1 asset: 1 Ph 3 | VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026Vebreltinib · Phase 1/2 | $48M | $3.3MDec 2025 | ~4.1 qtrswith a later raise | $5.5M |
Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis ImperfectaPartial signal | Jan 2027setrusumab · Phase 3 | $46M | $26MSep 2026 | ~4.0 qtrs | $13M |
MiNK Therapeutics, Inc.INKT · Nasdaq | 1 asset: 1 Ph 2 | agenT-797Phase 2 · Gastric CancerWeak signal | Jun 2027agenT-797 · Phase 2 | $45M | $7.5MSep 2026 | ~4.2 qtrs | $6.4M |
Aldeyra TherapeuticsALDX · Nasdaq | 1 asset: 1 Ph 3 | reproxalapPhase 3 · Dry Eye DiseasePartial signal | None on record | $41M | $41MSep 2026 | ~8.6 qtrs | $12M |
Biomea FusionBMEA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | IcovamenibPhase 2 · Type 2 DiabetesPartial signal | Mar 2027Icovamenib · Phase 2 | $39M | $27MSep 2026 | ~2.4 qtrs | $35M |
Skye BioscienceSKYE · Nasdaq | 1 asset: 1 Ph 2 | nimacimabPhase 2 · Obesity | None on record | $36M | $4.8MSep 2026 | ~0.6 qtrs | $25M |
Grace TherapeuticsGRCE · Nasdaq | 1 asset: 1 Ph 3 | Nimodipine (GTx-104)Phase 3 · Subarachnoid Hemorrhage | None on record | $36M | $21MSep 2026 | ~8.2 qtrs | ~$2.6M |
INmune BioINMB · Nasdaq | 1 asset: 1 Ph 2 | PegipanerminPhase 2 · Alzheimer's DiseasePartial signal | None on record | $32M | $16MSep 2026 | ~5.1 qtrs | $17M |
ProMIS Neurosciences, Inc.PMN · Nasdaq | 1 asset: 1 Ph 1 | PMN310Phase 1 · Alzheimer's Disease | Dec 2026PMN310 · Phase 1 | $28M | $44MSep 2026 | ~4.3 qtrs | $33M |
Rockwell MedicalRMTI · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $25M | $23MSep 2026 | Cash-flow positive | $0.1M |
ABVC BioPharmaABVC · Nasdaq | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 | $24M | $0.1MSep 2026 | Ended Oct 2026 | $0.1M |
CervoMed Inc.CRVO · Nasdaq | 1 asset: 1 Ph 2 | neflamapimodPhase 2 · Dementia with Lewy BodiesPartial signal | None on record | $22M | $20MSep 2026 | ~2.9 qtrs | $19M |
Enlivex TherapeuticsENLV · Nasdaq | 1 asset: 1 Ph 2 | AllocetraPhase 2 · Osteoarthritis | Feb 2027Allocetra · Phase 2 | $20M | $6.2MDec 2025 | Ended Aug 2026 | $9.2M |
BeyondSpring PharmaceuticalsBYSI · Nasdaq | 1 asset: 1 Ph 3 | PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Jun 2029Plinabulin · Phase 3 | $19M | $6.5MJun 2026 | Ended Nov 2026 | $4.6M |
ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq | 1 asset: 1 Ph 2 | (Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026(Z)-endoxifen · Phase 2 | $18M | $21MSep 2026 | ~2.3 qtrs | $19M |
Lipocine Inc.LPCN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $17M | $21MSep 2026 | ~8.6 qtrs | $9.5M |
Cellectar Biosciences, Inc.CLRB · Nasdaq | 1 asset: 1 Ph 3 | Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal | 30 Jun 2027Iopofosine I-131 · Phase 1 | $15M | $25MSep 2026 | ~4.0 qtrs | $16M |
Seres TherapeuticsMCRB · Nasdaq | 1 asset: 1 Ph 1 | SER-155Phase 1 · Bacterial Infections in Allogeneic Stem Cell Transplant | None on record | $15M | $21MSep 2026 | ~1.3 qtrs | $40M |
Allarity Therapeutics, Inc.ALLR · Nasdaq | 1 asset: 1 Ph 2 | stenoparibPhase 2 · Ovarian Cancer | Mar 2027stenoparib · Phase 2 | $14M | — | ~7.9 qtrsJun 2026 | $8.5M |
Matinas BioPharmaMTNB · Nasdaq | 1 asset: 1 Ph 3 | Amphotericin B (MAT2203)Phase 3 · Cryptococcal Meningitis | None on record | $13M | $0.8MJun 2026 | Ended Aug 2026 | $0.1M |
BioCardiaBCDA · Nasdaq | 1 asset: 1 Ph 3 | CardiAMPPhase 3 · Heart FailurePartial signal | 1 Apr 2027CardiAMP · Phase na | $12M | $2.2MSep 2026 | ~1.2 qtrs | $4.5M |
Pluri Inc.PLUR · Nasdaq | 1 asset: 1 other | PLX-PADOsteoarthritis | None on record | $11M | $9.8MSep 2026 | ~2.0 qtrs | ~$25M |
Lisata TherapeuticsLSTA · Nasdaq | 2 assets: 2 Ph 2 | MAR001Phase 2 · HypertriglyceridemiaWeak signal | Nov 2027MAR001 · Phase 2 | $11M | $283MSep 2026 | 10+ years | $8.1M |
Ainos, Inc.AIMD · Nasdaq | 1 asset: 1 other | Interferon alfa (Veldona)Oral Warts in HIV Patients | None on record | $8.9M | $1.4MJun 2026 | Ended Oct 2026 | $7.7M |
VistaGen TherapeuticsVTGN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | fasedienolPhase 3 · Social Anxiety DisorderPartial signal | None on record | $8.9M | $20MSep 2026 | ~1.4 qtrs | ~$48M |
Kyntra BioKYNB · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Oct 2027Roxadustat · Phase 3 | $7.9M | $91MJun 2026 | ~9.6 qtrs | $23M |
MoleculinMBRX · Nasdaq | 1 asset: 1 Ph 3 | AnnamycinPhase 2/3 · Acute Myeloid Leukemia | Aug 2029Annamycin · Phase 2/3 | $7.2M | $7.3MSep 2026 | ~1.1 qtrs | $20M |
MetaViaMTVA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | VanoglipelPhase 2 · MASH / NASHWeak signal | None on record | $7.1M | $8.8MSep 2026 | ~2.1 qtrs | $19M |
BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq | 1 asset: 1 Ph 3 | BezisterimPhase 3 · Alzheimer's DiseasePartial signal | None on record | $7.1M | $7.7MSep 2026 | ~1.7 qtrs | ~$14M |
Exicure, Inc.XCUR · Nasdaq | 1 asset: 1 Ph 2 | Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signal | None on record | $6.8M | $1.7MJun 2026 | Ended Oct 2026 | $2.0M |
Tempest TherapeuticsTPST · Nasdaq | 1 asset: 1 Ph 3 | AmezalpatPhase 3 · Hepatocellular Carcinoma | Dec 2028Amezalpat · Phase 3 | $6.2M | $0.9MSep 2026 | Ended Oct 2026 | $2.7M |
SoligenixSNGX · Nasdaq | 1 asset: 1 Ph 3 | Synthetic hypericinPhase 3Reliable signal | None on record | $5.9M | $9.0MSep 2026 | ~4.7 qtrs | $5.1M |
Kiora Pharmaceuticals, Inc.KPRX · Nasdaq | 1 asset: 1 Ph 2 | KIO-301Phase 2 · Retinitis Pigmentosa | Aug 2027KIO-301 · Phase 2 | $5.2M | $16MSep 2026 | ~8.4 qtrs | $9.1M |
Alzamend NeuroALZN · Nasdaq | 1 asset: 1 Ph 2 | Lithium salicylate/L-proline (AL001)Phase 1/2 · Alzheimer's DiseaseWeak signal | Jul 2027Lithium salicylate/L-proline (AL001) · Phase 1/2 | $5.0M | $7.6MJul 2026 | ~4.7 qtrs | ~$4.3M |
BioLineRx Ltd.BLRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $5.0M | $3.3MDec 2025 | Ended Oct 2026with a later raise | $8.1M |
PulmatrixPULM · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | Itraconazole (PUR1900)Phase 2 · Allergic Bronchopulmonary Aspergillosis | None on record | $4.9M | $2.2MJun 2026 | ~2.2 qtrs | <$0.1M |
Processa Pharmaceuticals, Inc.PCSA · Nasdaq | 1 asset: 1 Ph 2 | PCS499Phase 2 · Necrobiosis Lipoidica | None on record | $4.8M | $180MSep 2026 | 10+ years | $6.4M |
Alaunos Therapeutics, Inc.TCRT · Nasdaq | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | None on record | $4.4M | $0.1MJun 2026 | Ended Jul 2026 | $1.6M |
GRI Bio, Inc.GRI · Nasdaq | 1 asset: 1 other | GRI-0803Systemic Lupus Erythematosus | None on record | $2.8M | $9.5MSep 2026 | ~4.0 qtrs | $2.5M |
Jaguar HealthJAGX · Nasdaq | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 | $1.7M | $6.6MJun 2026 | ~3.9 qtrs | $25M |
Genprex, Inc.GNPX · Nasdaq | 1 asset: 1 Ph 2 | Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Quaratusugene Ozeplasmid · Phase 1/2 | $1.4M | $15MSep 2026 | ~4.0 qtrs | $10M |
Aptevo TherapeuticsAPVO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | ALG.APV-527Phase 1/2 · Solid Tumors | Oct 2027Mipletamig · Phase 1 | $0.8M | $9.8MJun 2026 | ~1.6 qtrs | $15M |
Agomab Therapeutics NVAGMB · Nasdaq | 1 asset: 1 Ph 2 | ontunisertibPhase 2 · Fibrostenosing Crohn's Disease | None on record | — | — | — | — |
Aligos TherapeuticsALGS · Nasdaq | 1 asset: 1 Ph 2 | ALG-055009Phase 2 · MASH / NASH | None on record | — | $32MSep 2026 | ~1.9 qtrs | $83M |
Alkermes plcALKS · Nasdaq | 6 assets: 5 approved, 1 Ph 3 | AlixorextonPhase 3 · Narcolepsy | Nov 2026Alixorexton · Phase 2 | — | $755MSep 2026 | Cash-flow positive | $430M |
Alpha Compute CorpALP · Nasdaq | 2 assets: 2 Ph 2 | TT-10Phase 1/2 · Non-Small Cell Lung Cancer | 1 Dec 2028TT-10 · Phase 1/2 | — | $0.2MSep 2025 | Ended Oct 2025 | ~$5.4M |
AlvotechALVO · Nasdaq | 4 assets: 2 approved, 2 other | Aflibercept (Afiveg)Age-Related Macular Degeneration | None on record | — | $172MDec 2025 | ~26.3 qtrswith a later raise | $184M |
Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq | 4 assets: 4 approved | Approved assets only | None on record | — | $231MSep 2026 | Cash-flow positive | $92M |
ANI Pharmaceuticals, Inc.ANIP · Nasdaq | 4 assets: 4 approved | Approved assets only | 18 Dec 2029Anastrozole · Phase 3 | — | $421MSep 2026 | Cash-flow positive | $51M |
argenxARGX · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record | — | $702MDec 2023 | — | — |
Ascendis Pharma A/SASND · Nasdaq | 2 assets: 2 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | $724MDec 2025 | Cash-flow positive | $344M |
Aurinia PharmaceuticalsAUPH · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | aritinerceptPhase 1/2 · Generalized Myasthenia Gravis | 2 Mar 2029aritinercept · Phase 1/2 | — | $487MSep 2026 | Cash-flow positive | $48M |
BicycleTx LimitedBCYC · Nasdaq | 2 assets: 2 Ph 2 | Nuzefatide pevedotinPhase 2 · Pancreatic Ductal Adenocarcinoma | 31 Dec 2026Nuzefatide pevedotin · Phase 1/2 | — | $470MSep 2026 | ~10.7 qtrs | $175M |
Bright Minds Biosciences Inc.DRUG · Nasdaq | 1 asset: 1 Ph 2 | BMB-101Phase 2 · Epilepsy | Nov 2026BMB-101 · Phase 2 | — | $4.2MSep 2024 | ~12.4 qtrs | $0.9M |
Can-Fite BioPharmaCANF · Nasdaq | 2 assets: 2 Ph 3 | NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal | 31 Aug 2027Piclidenoson · Phase 2 | — | $8.5MDec 2025 | Ended Mar 2026 | $6.7M |
Catalyst Pharmaceuticals, Inc.CPRX · Nasdaq | 1 asset: 1 approved | Approved assets only | 6 Apr 2027Perampanel · Phase 2 | —no price since 14 Jul 2026 | — | — | — |
Connect BiopharmaCNTB · Nasdaq | 1 asset: 1 Ph 3 | RademikibartPhase 3 · Atopic DermatitisPartial signal | 31 Dec 2026Rademikibart · Phase 3 | — | $31MJun 2026 | ~2.1 qtrs | $54M |
Enanta Pharmaceuticals, Inc.ENTA · Nasdaq | 2 assets: 2 Ph 2 | EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signal | Dec 2026zelicapavir · Phase 2 | — | $190MJun 2026 | ~18.8 qtrs | $93M |
Galmed Pharmaceuticals Ltd.EOCN · Nasdaq | 1 asset: 1 Ph 3 | AramcholPhase 3 · MASH / NASH | None on record | — | $8.8MJun 2026 | ~3.2 qtrs | $5.6M |
Genenta Science S.p.A.GNTA · Nasdaq | 1 asset: 1 Ph 2 | TemferonPhase 1/2 · Glioblastoma | None on record | —no price since 3 Nov 2026 | $33MDec 2025 | ~17.0 qtrs | $3.1M |
| 1 asset: 1 Ph 2 | CR-001Phase 1/2 · Solid Tumors | Feb 2029CR-001 · Phase 1/2 | — | $289MSep 2026 | ~14.1 qtrs | $177M | |
Immuneering CorporationIMRX · Nasdaq | 1 asset: 1 Ph 3 | AtebimetinibPhase 3 · Pancreatic Cancer | Jun 2027Atebimetinib · Phase 1/2 | — | $145MSep 2026 | ~9.4 qtrs | $55M |
Immunocore Holdings plcIMCR · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | brenetafuspPhase 3 · Cutaneous Melanoma | 16 Oct 2027brenetafusp · Phase 3 | — | $901MSep 2026 | 10+ years | $289M |
Indivior Pharmaceuticals, Inc.INDV · Nasdaq | 3 assets: 3 approved | Approved assets only | None on record | —no price since 2 Nov 2026 | $305MSep 2026 | Cash-flow positive | $54M |
Inmagene BiopharmaceuticalsIMA · Nasdaq | 1 asset: 1 Ph 2 | OlevaprubartPhase 2 · Atopic DermatitisWeak signal | Dec 2027Olevaprubart · Phase 2 | — | $127MSep 2026 | ~13.9 qtrs | $29M |
KamadaKMDA · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | — | $75MDec 2025 | Cash-flow positive | $13M |
Karyopharm TherapeuticsKPTI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | EltanexorPhase 1/2 · Multiple MyelomaWeak signal | Dec 2026Selinexor · Phase 2/3 | —no price since 10 Nov 2026 | $65MJun 2026 | ~4.0 qtrs | $121M |
Kiniksa PharmaceuticalsKNSA · Nasdaq | 1 asset: 1 Ph 2 | vixarelimabPhase 2 · Ulcerative ColitisPartial signal | 25 Aug 2027vixarelimab · Phase 2 | — | $569MSep 2026 | Cash-flow positive | $136M |
Lifeward Ltd.LFWD · Nasdaq | 1 asset: 1 Ph 3 | ORMD-0801Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $5.0MSep 2026 | ~1.0 qtrs | $10M |
MeiraGTx LimitedMGTX · Nasdaq | 1 asset: 1 Ph 2 | AAV-GAD gene therapyPhase 2 · Parkinson's DiseaseWeak signal | Oct 2029AAV-GAD gene therapy · Phase 1/2 | — | $187MSep 2026 | Cash-flow positive | $160M |
NanobiotixNBTX · Nasdaq | 1 asset: 1 Ph 3 | NBTXR3Phase 3 · Head and Neck Squamous Cell Carcinoma | 30 Apr 2027NBTXR3 · Phase 1 | — | $62MDec 2025 | ~6.5 qtrs | $26M |
Obsidian Therapeutics, Inc.OBX · Nasdaq | 1 asset: 1 Ph 2 | OBX-115Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2029OBX-115 · Phase 1/2 | — | $216MSep 2026 | ~11.2 qtrs | $89M |
Prothena Biosciences LimitedPRTA · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | PrasinezumabPhase 3 · Parkinson's Disease | 17 Dec 2026Moponetug · Phase 2 | — | $272MSep 2026 | ~9.6 qtrs | $83M |
Quince TherapeuticsQNCX · Nasdaq | 1 asset: 1 Ph 2 | LAM-001Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | None on record | —no price since 9 Oct 2026 | $105MSep 2026 | ~8.6 qtrs | $31M |
Radiopharm Theranostics, LtdRADX · Nasdaq | 4 assets: 2 Ph 2, 2 Ph 1 | RAD101Phase 2 · Brain Metastases | Dec 2027RAD202 · Phase 1 | — | $29MJun 2025 | Ended May 2026with a later raise | $28M |
REGENXBIO Inc.RGNX · Nasdaq | 3 assets: 3 Ph 3 | Surabgene lomparvovecPhase 3 · Age-Related Macular DegenerationWeak signal | Dec 2026Surabgene lomparvovec · Phase 2/3 | — | $251MSep 2026 | ~6.6 qtrs | $234M |
Roivant Sciences Ltd.ROIV · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | ImeroprubartPhase 3 · Myasthenia Gravis | Dec 2026Mosliciguat · Phase 2 | — | $4.2BSep 2026 | 10+ years | ~$678M |
Sagimet Biosciences Inc.SGMT · Nasdaq | 1 asset: 1 Ph 3 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Aug 2027Denifanstat · Phase 3 | — | $236MSep 2026 | ~31.5 qtrswith a later raise | $42M |
Summit TherapeuticsSMMT · Nasdaq | 1 asset: 1 Ph 3 | IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2026Ivonescimab · Phase 3 | — | $630MSep 2026 | ~4.8 qtrs | $80M |
TG THERAPEUTICS, INC.TGTX · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | $505MSep 2026 | Cash-flow positive | $236M |
Tiziana Life Sciences Ltd.TLSA · Nasdaq | 1 asset: 1 Ph 2 | ForalumabPhase 2 · Multiple Sclerosis | 1 Apr 2027Foralumab · Phase 2 | — | $3.7MDec 2024 | ~9.7 qtrs | $5.2M |
TScan Therapeutics, Inc.TCRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | TSC-101Phase 3 · Hematologic Malignancies | Jun 2029TSC-101 · Phase 3 | — | $78MSep 2026 | ~2.8 qtrs | $91M |
XBiotechXBIT · Nasdaq | 2 assets: 2 Ph 2 | NatrunixPhase 2 · Rheumatoid ArthritisPartial signal | 15 Jan 2027Natrunix · Phase 2 | — | $105MSep 2026 | ~10.3 qtrs | $47M |
Zai LabZLAB · Nasdaq | 7 assets: 6 approved, 1 Ph 1 | ZL-1503Phase 1 · Atopic Dermatitis | 24 Nov 2026Xanomeline/trospium chloride · Phase 3 | — | $560MSep 2026 | ~10.7 qtrs | $239M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.